Kewin Otazu
Research Subjects
Kewin Otazu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Georcki Ropón-Palacios
Laboratório de Modelagem Computacional - LaModel, Instituto de Ciências Exatas - ICEx, Universidade Federal de Alfenas - UNIFAL-, MG, Alfenas Minas Gerais, Brazil
4 shared publications - Gustavo Enrique Olivos-Ramirez
Institute of Fundamental Technological Research of the Polish Academy of Sciences. Warsaw, Poland
4 shared publications - Ihosvany Camps
Laboratório de Modelagem Computacional -LaModel Instituto de Ciências Exatas -ICEx. Universidade Federal de Alfenas -UNIFAL-MG Alfenas Minas Gerais Brazil
4 shared publications - Manuel Enrique Chenet Zuta
Universidad Nacional Mayor de San Marcos
4 shared publications - Cinthia Aguiar
Laboratório de Modelagem Computacional - LaModel, Instituto de Ciências Exatas - ICEx. Universidade Federal de Alfenas - UNIFAL-MG, Alfenas, Minas Gerais, Brazil
1 shared publication - Cleidy Osorio-Mogollón
Ribeirão Preto Medical School, University of São Paulo
1 shared publication
Latest Publications
- 23 June 2022
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 20 (7) , 808-820
Attacking the SARS-CoV-2 Replication Machinery with the Pathogen Box’s Molecules
Introduction: The world is currently facing a pandemic caused by the new coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. Viral transcription and replication are within the fundamental processes of any virus. They allow the synthesis of genetic material and the consequent multiplication of the virus to infect other cells or organisms. Methods: The most important protein in SARS-CoV-2 is the RNA polymerase (RdRp or nsp12), responsible for both processes. The structure of this protein (PDB ID: 6M71) was used as a target in the application of computational strategies for drug search, like virtual screening and molecular docking. Here, Pathogen Box database of chemical compounds was used together with Remdesivir, Beclabuvir, and Sofosbuvir drugs as potential inhibitors of nsp12. Results: The results showed a Top10 potential target inhibitor, with binding energy (∆G) higher than those of the positive controls, of which TCMDC-134153 and TCMDC-135052, both with ∆G = −7.53 kcal/mol, present interactions with three important residues of the nsp12 catalytic site. Conclusion: These proposed ligands would be used for subsequent validation by molecular dynamics, where they can be considered as drugs for the development of effective treatments against this new pandemic.
- 23 June 2022
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 20 (7) , 808-820
Attacking the SARS-CoV-2 Replication Machinery with the Pathogen Box’s Molecules
Introduction: The world is currently facing a pandemic caused by the new coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. Viral transcription and replication are within the fundamental processes of any virus. They allow the synthesis of genetic material and the consequent multiplication of the virus to infect other cells or organisms. Methods: The most important protein in SARS-CoV-2 is the RNA polymerase (RdRp or nsp12), responsible for both processes. The structure of this protein (PDB ID: 6M71) was used as a target in the application of computational strategies for drug search, like virtual screening and molecular docking. Here, Pathogen Box database of chemical compounds was used together with Remdesivir, Beclabuvir, and Sofosbuvir drugs as potential inhibitors of nsp12. Results: The results showed a Top10 potential target inhibitor, with binding energy (∆G) higher than those of the positive controls, of which TCMDC-134153 and TCMDC-135052, both with ∆G = −7.53 kcal/mol, present interactions with three important residues of the nsp12 catalytic site. Conclusion: These proposed ligands would be used for subsequent validation by molecular dynamics, where they can be considered as drugs for the development of effective treatments against this new pandemic.
- Open Access
- 23 March 2022
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 98, 107668
Glycosylation is key for enhancing drug recognition into spike glycoprotein of SARS-CoV-2
- 23 March 2022
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 98, 107668
Open AccessGlycosylation is key for enhancing drug recognition into spike glycoprotein of SARS-CoV-2
- 22 August 2019
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 38 (11) , 3225-3234
Potential novel inhibitors against emerging zoonotic pathogen Nipah virus: a virtual screening and molecular dynamics approach
Nipah virus is a pathogen considered highly infectious, and its lethality can cause between 40% and 70% of deaths in those infected. At present, no effective treatment is available which results in an imperative need to explore new approaches to the search for drugs. Through virtual screening techniques, docking and molecular dynamics, 183 ligands were evaluated against the Nipah virus glycoprotein (NiV-G), involved throughout the process of virus entry to the host cell, resulting in a good target for blocking the infection. Of the 183 drugs computationally screened, three of them (MMV020537, MMV688888 and MMV019838) were found to be potential inhibitors of NiV-G. Their calculated dissociation constants were 0.03 nM, 2.18 nM and 31.61 nM, respectively. Molecular dynamics studies confirm their stability binding modes in the active site of the protein. These potential inhibitors can be used later as leads for the development of new drugs that allow effective treatment of the disease. Communicated by Ramaswamy H. Sarma
- 22 August 2019
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 38 (11) , 3225-3234
Potential novel inhibitors against emerging zoonotic pathogen Nipah virus: a virtual screening and molecular dynamics approach
Nipah virus is a pathogen considered highly infectious, and its lethality can cause between 40% and 70% of deaths in those infected. At present, no effective treatment is available which results in an imperative need to explore new approaches to the search for drugs. Through virtual screening techniques, docking and molecular dynamics, 183 ligands were evaluated against the Nipah virus glycoprotein (NiV-G), involved throughout the process of virus entry to the host cell, resulting in a good target for blocking the infection. Of the 183 drugs computationally screened, three of them (MMV020537, MMV688888 and MMV019838) were found to be potential inhibitors of NiV-G. Their calculated dissociation constants were 0.03 nM, 2.18 nM and 31.61 nM, respectively. Molecular dynamics studies confirm their stability binding modes in the active site of the protein. These potential inhibitors can be used later as leads for the development of new drugs that allow effective treatment of the disease. Communicated by Ramaswamy H. Sarma